Dishman Carbogen Amcis Ltd (DCAL) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 540701 | NSE: DCAL | Pharmaceuticals & Drugs | Small Cap

Dishman Carbogen Amc Share Price

223.10 -5.50 -2.41%
as on 05-Dec'25 14:26

Dishman Carbogen Amcis Ltd (DCAL) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 540701 | NSE: DCAL | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Dishman Carbogen Amc

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Dishman Carbogen Amcis stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
26.28
Market Cap:
3,584.1 Cr.
52-wk low:
180
52-wk high:
321.2

Is Dishman Carbogen Amcis Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Dishman Carbogen Amc: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dishman Carbogen Amcis Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 0%4.6%4.7%5.8%3.9%-0.3%0.8%0.4%-0%2.3%-
Value Creation
Index
NA-0.7-0.7-0.6-0.7-1.0-1.0-1.0-1.0-0.8-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 01,7141,6952,0592,0441,9122,1412,4132,6162,7122,759
Sales YoY Gr.-NA-1.1%21.5%-0.7%-6.4%12%12.7%8.4%3.7%-
Adj EPS 0010.213.810.9-8.91.92.7-8.91.58.7
YoY Gr.-NANA35.2%-21.2%-181.9%NA42.5%-435.5%NA-
BVPS (₹) 00316.4333.3364.3363.5353.9370.5358.9371.9406
Adj Net
Profit
0159165223171-14029.241.5-13923.1136
Cash Flow from Ops. 0303226282585513355266384375-
Debt/CF from Ops. 03.14.83.71.82.346.95.15.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA5.8%8.2%3.7%
Adj EPS NA-33%-7.5%NA
BVPSNA0.4%1.7%3.6%
Share Price - 8.9% 30.7% -15.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
03.33.34.33.1-2.50.50.7-2.40.42.2
Op. Profit
Mgn %
026.626.927.925.215.215.51610.716.621.1
Net Profit
Mgn %
08.49.810.98.4-7.31.41.7-5.30.94.9
Debt to
Equity
0238.60.20.20.20.20.30.30.40.40.2
Working Cap
Days
00339308332346279254241239153
Cash Conv.
Cycle
0013912714215514115615716216

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Dishman Carbogen Amcis Ltd.

Standalone Consolidated
TTM EPS (₹) -2 8.7
TTM Sales (₹ Cr.) 326 2,759
BVPS (₹.) 253.3 406
Reserves (₹ Cr.) 3,939 6,334
P/BV 0.90 0.56
PE 0.00 26.28
From the Market
52 Week Low / High (₹) 180.00 / 321.15
All Time Low / High (₹) 46.45 / 396.55
Market Cap (₹ Cr.) 3,584
Equity (₹ Cr.) 31.4
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Dishman Carbogen Amc:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Dishman Carbogen Amc - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Dishman Carbogen Amc

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales1,7141,6952,0592,0441,9122,1412,4132,6162,712
Operating Expenses 1,2601,2571,5071,5461,6381,8152,0812,3522,272
Manufacturing Costs148132171178160207259314259
Material Costs329337404459468447517597502
Employee Cost 5966257157628739811,0301,2081,294
Other Costs 187162217147137179275233218
Operating Profit 453438552498274326332264440
Operating Profit Margin (%) 26.5%25.8%26.8%24.3%14.3%15.2%13.8%10.1%16.2%
Other Income 265354443949285151
Interest 49495762485786120159
Depreciation 214211240283308308281311294
Exceptional Items 0000-22-15-48-6-18
Profit Before Tax 216231309197-65-4-55-12219
Tax 71769839100-22-253116
Profit After Tax 145155210159-16518-30-1533
PAT Margin (%) 8.5%9.1%10.2%7.8%-8.6%0.8%-1.2%-5.9%0.1%
Adjusted EPS (₹)0.09.613.010.1-10.51.2-1.9-9.80.2
Dividend Payout Ratio (%)0%0%2%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 45,1075,3795,7155,6995,5495,8105,6285,832
Share Capital 03232313131313131
Reserves 45,0755,3475,6845,6675,5185,7785,5965,800
Minority Interest000000000
Debt8459188839301,0461,2551,7271,8661,805
Long Term Debt4605253622415047621,0472461,149
Short Term Debt3853935206885424936811,620655
Trade Payables86186195284169193220244231
Others Liabilities 5,6409578641,2651,4411,6371,6831,8332,120
Total Liabilities 6,5747,1697,3218,1938,3568,6349,4399,5719,986

Fixed Assets

Gross Block6,1876,6216,8977,8918,1558,6339,45810,30810,545
Accumulated Depreciation1,3401,5601,8052,2182,4622,8653,2753,5883,495
Net Fixed Assets 4,8475,0615,0925,6735,6935,7686,1836,7207,051
CWIP 1331511752344867801,043646467
Investments 4019616719117232424910297
Inventories427485549581516645804883900
Trade Receivables286444445577421473590484665
Cash Equivalents 876996161308172189413507
Others Assets 755764796776760472381322299
Total Assets 6,5747,1697,3218,1938,3568,6349,4399,5719,986

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 303226282585513355266379375
PBT 216231309197-65-4-55-12219
Adjustment 232235277330313325392377467
Changes in Working Capital -29-206-17413231690-38144-81
Tax Paid -116-34-130-74-51-56-34-19-30
Cash Flow From Investing Activity -142-297-169-442-380-619-494-230-192
Capex -139-205-308-409-365-455-618-303-215
Net Investments 3-14868-2821-171104150-1
Others -65671-6-36821-7624
Cash Flow From Financing Activity -13778-102-98-11130250-22-102
Net Proceeds from Shares -100000000
Net Proceeds from Borrowing -98118-172-15416928216750194
Interest Paid -52-49-57-61-53-60-73-99-151
Dividend Paid -1900-300000
Others 338127121-127-9215626-145
Net Cash Flow 2371146122-1332212881

Finance Ratio

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)3654.026.054.012.86-2.890.32-0.52-2.680.06
ROCE (%)4.64.675.793.93-0.260.760.43-0.032.31
Asset Turnover Ratio0.260.250.280.260.230.250.270.280.28
PAT to CFO Conversion(x)2.091.461.343.68N/A19.72N/AN/A125
Working Capital Days
Receivable Days617979919576807577
Inventory Days91989210110599110118120
Payable Days95147172190177148146142173

Dishman Carbogen Amcis Ltd Stock News

Dishman Carbogen Amcis Ltd FAQs

The current trading price of Dishman Carbogen Amc on 05-Dec-2025 14:26 is ₹223.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Dishman Carbogen Amc stood at ₹3,584.1.
The latest P/E ratio of Dishman Carbogen Amc as of 04-Dec-2025 is 0.00.
The latest P/B ratio of Dishman Carbogen Amc as of 04-Dec-2025 is 0.90.
The 52-week high of Dishman Carbogen Amc is ₹321.1 and the 52-week low is ₹180.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dishman Carbogen Amc is ₹326.3 ( Cr.) .

About Dishman Carbogen Amcis Ltd

Incorporated in 1983, Dishman Carbogen Amcis Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, the company is a leading global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up, and manufacturing services.

The company aids drug innovators for development and process optimization for novel drug molecules in various stages of the development process. Once the innovative molecules are approved, the company further explore the possibility of large scale commercial supply tie-ups. The company is generating a healthy pipeline of contract manufacturing opportunities commensurate to the growing revenue base of manufacturing. Its robust business model is capable of sustaining growth, with CRAMS being the focal point of all its strategic efforts.

Business area of the company

The company is a fully integrated CRAMS player working with global pharmaceutical innovators. It has a global presence with development and manufacturing facilities across Europe, India, and China. It provides end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.

Products and services

  • CRAMS
  • Vitamin D & Analogues
  • Disinfectants
  • Highly Potent API Supply
  • Niche Generic API
  • Speciality Chemicals

History and Milestones

  • 1983: Incorporation of Dishman Pharmaceutical and Chemicals Limited.
  • 1989: Commencing production of Phase Transfer Catalysts at Naroda facility.
  • 1995: Entered into a JV with Schutz & Co. for manufacturing Chlorhexidine and Derivatives for European market.
  • 1996: Commencement of Bavla facility for Bulk Intermediates.
  • 2001: First commercial contract manufacturing agreement signed with a major western pharmaceutical company.
  • 2004: Came out with an IPO on Indian stock exchanges.
  • 2005: Acquisition of Synprotec - DCR (now known as CARBOGEN AMCIS Ltd, UK).
  • 2006: Acquisition of CARBOGEN AMCIS - a Swiss based CRAMS player.
  • 2007: Acquisition of Solvay Pharmaceuticals’ Vitamins and Chemicals business (now known as CARBOGEN AMCIS BV).
  • 2010: Commenced Dishman Shanghai manufacturing facility.
  • 2012: Acquisition of Riom (France) - CARBOGEN AMCIS SAS.
  • 2014: Acquisition of Vionnaz (CH) site - CARBOGEN AMCIS.
  • 2017: Change of name of the parent to Dishman Carbogen Amcis Limited, reinforcing the synergies between Dishman and Carbogen Amcis brands.
  • 2020: Global Reorganization of Roles and Responsibilities of the Management Team.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×